Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is a Principal Investigator on the national Accelerating Clinical Trials (ACT) Consortium and CANTRAIN Clinical Trials Training Platform, both funded by CIHR. He was also the co-lead of the Rethinking Clinical Trials (REaCT) Program which performs practical patient-focused research that ensures that patients receive optimal, safe, cost-effective treatment. Dr. Fergusson is a principal investigator on a number of large, peer-reviewed clinical trials in transfusion medicine including “An innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS), “Blood Conservation Using Antifibrinolytics: Randomized Trial in High-Risk Cardiac Surgery (BART)”, Age of Red Blood Cells in Premature Infants (ARIPI), and “Age of Blood Evaluation (ABLE)”. Dr. Fergusson has contributed over 744 full journal articles to the medical literature.